Jeffrey W. Albers is of Blueprint Medicines Corp. Currently has a direct ownership of 157,557 shares of BPMC, which is worth approximately $13.8 Million. The most recent transaction as insider was on Sep 09, 2024, when has been sold 19,702 shares (Common Stock) at a price of $85.49 per share, resulting in proceeds of $1,684,323. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 158K
5.8% 3M change
10.5% 12M change
Total Value Held $13.8 Million

Jeffrey W. Albers Transaction History

Date Transaction Value Shares Traded Shares Held Form
Sep 09 2024
SELL
Open market or private sale
$1,684,323 $85.49 p/Share
19,702 Reduced 11.11%
157,557 Common Stock
Sep 09 2024
BUY
Exercise of conversion of derivative security
$360,500 $36.05 p/Share
10,000 Added 5.34%
177,259 Common Stock
Jun 12 2024
BUY
Grant, award, or other acquisition
-
2,242 Added 1.32%
167,259 Common Stock
Mar 20 2024
SELL
Open market or private sale
$2,189,625 $87.33 p/Share
25,073 Reduced 12.47%
176,050 Common Stock
Mar 20 2024
BUY
Exercise of conversion of derivative security
$211,616 $8.44 p/Share
25,073 Added 11.08%
201,123 Common Stock
Mar 07 2024
SELL
Open market or private sale
$1,000,582 $90.69 p/Share
11,033 Reduced 6.27%
165,017 Common Stock
Jan 25 2024
SELL
Open market or private sale
$2,057,500 $82.3 p/Share
25,000 Reduced 12.43%
176,050 Common Stock
Jan 25 2024
BUY
Exercise of conversion of derivative security
$211,000 $8.44 p/Share
25,000 Added 11.06%
201,050 Common Stock
Dec 11 2023
SELL
Open market or private sale
$395,349 $79.07 p/Share
5,000 Reduced 2.76%
176,050 Common Stock
Dec 11 2023
BUY
Exercise of conversion of derivative security
$180,250 $36.05 p/Share
5,000 Added 2.69%
181,050 Common Stock
Nov 30 2023
SELL
Open market or private sale
$352,750 $70.55 p/Share
5,000 Reduced 2.76%
176,050 Common Stock
Nov 30 2023
BUY
Exercise of conversion of derivative security
$180,250 $36.05 p/Share
5,000 Added 2.69%
181,050 Common Stock
Nov 24 2023
SELL
Open market or private sale
$1,012,950 $67.53 p/Share
15,000 Reduced 7.85%
176,050 Common Stock
Nov 24 2023
BUY
Exercise of conversion of derivative security
$28,050 $1.87 p/Share
15,000 Added 7.28%
191,050 Common Stock
Nov 03 2023
SELL
Open market or private sale
$89,293 $60.13 p/Share
1,485 Reduced 0.84%
176,050 Common Stock
Nov 03 2023
BUY
Exercise of conversion of derivative security
$53,534 $36.05 p/Share
1,485 Added 0.83%
177,535 Common Stock
Nov 02 2023
SELL
Open market or private sale
$281,330 $60.71 p/Share
4,634 Reduced 2.56%
176,050 Common Stock
Nov 02 2023
BUY
Exercise of conversion of derivative security
$167,055 $36.05 p/Share
4,634 Added 2.5%
180,684 Common Stock
Nov 01 2023
SELL
Open market or private sale
$232,937 $60.02 p/Share
3,881 Reduced 2.16%
176,050 Common Stock
Nov 01 2023
BUY
Exercise of conversion of derivative security
$139,910 $36.05 p/Share
3,881 Added 2.11%
179,931 Common Stock
Sep 28 2023
SELL
Open market or private sale
$346,072 $50.17 p/Share
6,898 Reduced 3.77%
176,050 Common Stock
Sep 28 2023
BUY
Exercise of conversion of derivative security
$12,899 $1.87 p/Share
6,898 Added 3.63%
182,948 Common Stock
Sep 27 2023
SELL
Open market or private sale
$900,755 $49.76 p/Share
18,102 Reduced 9.32%
176,050 Common Stock
Sep 27 2023
BUY
Exercise of conversion of derivative security
$33,850 $1.87 p/Share
18,102 Added 8.53%
194,152 Common Stock
Aug 25 2023
SELL
Open market or private sale
$501,599 $50.16 p/Share
10,000 Reduced 5.37%
176,050 Common Stock

Also insider at

KYMR
Kymera Therapeutics, Inc. Healthcare
MGTA
Magenta Therapeutics, Inc. Healthcare
AGLE
Aeglea BioTherapeutics, Inc. Healthcare
JWA

Jeffrey W. Albers

Cambridge, MA

Track Institutional and Insider Activities on BPMC

Follow Blueprint Medicines Corp and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells BPMC shares.

Notify only if

Insider Trading

Get notified when an Blueprint Medicines Corp insider buys or sells BPMC shares.

Notify only if

News

Receive news related to Blueprint Medicines Corp

Track Activities on BPMC